Page 3 - Subgroup Analysis News Today

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych Congress 2023. The...

/PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the...

/PRNewswire/ -- Today, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review...

A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.

A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39... | May 11, 2023

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M...

FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom ... | May 9, 2023

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--May 8, 2023--

Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful